Relationship Between 18F-Fluorodeoxyglucose Uptake and V-Ki-Ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog Mutation in Colorectal Cancer Patients: Variability Depending on C-Reactive Protein Level. Issue 1 (January 2016)

• Record Type: Journal Article
• Authors: Lee, Jae-Hoon; Kang, Jeonghyun; Baik, Seung Hyuk; Lee, Kang Young; Lim, Beom Jin; Jeon, Tae Joo; Ryu, Young Hoon; Sohn, Seung-Kook
• Editors: Banswal., Lalit
• Is Part Of: Medicine. Volume 95:Issue 1(2016)
• Page Start: e2236
• Publication Date: 2016-01
• Subjects: Medicine -- Periodicals; Medicine -- Periodicals; Médecine -- Périodiques; Geneeskunde; Medicine; Periodicals; Periodicals; 610.5
• DOI: 10.1097/MD.0000000000002236
• Languages: English
• ISSNs: 0025-7974

Abstract

Abstract : Abstract: To evaluate clinical values of clinicopathologic and 18 F-fluorodeoxyglucose ( 18 F-FDG) positron emission tomography/computed tomography (PET/CT)-related parameters for prediction of v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation in colorectal cancer (CRC) and to investigate their variability depending on C-reactive protein (CRP) levels. In total, 179 CRC patients who underwent PET/CT scans before curative resection and KRAS mutation evaluation following surgery were enrolled. Maximum standardized uptake value (SUVmax ), peak standardized uptake value (SUVpeak ), metabolic tumor volume, and total lesion glycolysis were determined semiquantitatively. Associations between clinicopathologic and PET/CT-related parameters and KRAS expression were analyzed. Elevated CRP (>6.0 mg/L; n = 47) was associated with higher primary tumor size, higher SUVmax, SUVpeak, metabolic tumor volume, and total lesion glycolysis, compared with those for the group with a CRP lower than that the cutoff value (<6.0 mg/L; n = 132). Interestingly, the CRC patients (having CRP < 6.0 mg/L) with KRAS mutations had significantly higher ( P < 0.05) SUVmax and SUVpeak values than the patients expressing wild-type KRAS mutations. Multivariate analysis revealed SUVmax and SUVpeak to be significantly associated with KRAS mutations (odds ratio = 3.3, P = 0.005, and odds ratio = 3.9, P = 0.004), together with histologic grade and lymph node metastasis. 18 F-FDG uptake was significantly higher in CRC patients with KRAS mutations and with normal CRP levels. A severe local inflammation with raised CRP levels, however, might affect accurate 18 F-FDG quantification in CRC tumors. Positron emission tomography/computed tomography-related parameters could supplement genomic analysis to determine KRAS expression in CRC; however, care should be exercised to guarantee proper patient selection.